Synovial sarcoma (SS), an often lethal sarcoma occurring predominantly in young adults, is defined by a specific chromosomal translocation, t(X;18), which fuses the SYT gene on chromosome 18 to either the SSXl or the SSX2 gene on chromosome X. The SYT-SSX fusion oncoprotein functions as aberrant transcriptional protein that SYT-SSX exerts its transcriptional effects by interacting with histone-modifying enzymes, leading to a deregulation of epigenetic control of gene expression. The present proposal brings together expertise in fundamental histone code biology with experience in synovial sarcoma cell line- and human tissue-based translational research to develop a deeper understanding of SYT-SSX-dependent histone code alterations that could lead to more rational, more precisely targeted, and, hopefully, more effective epigenetic therapy for synovial sarcoma. The proposed work addresses the central role of SYTSSX- dependent epigenetic alterations in the biology of synovial sarcoma from three complementary perspectives: mechanistic (Aim 1), global genomic (Aim 2), and preclinical (Aim 3). Certain cancers are thought to arise from genetic rearrangements that join separate genes to produce new fusion genes with abnormal functions. The SYT-SSX fusion gene in synovial sarcoma is such a gene. Understanding and targeting the biological mechanisms used by these cancer-causing fusion genes can lead to effective therapeutics, as exemplified by imatinib targeting BCR-ABL in chronic myelogenous leukemia and all-trans retinoic acid targeting PML-RARa in acute promyelocytic leukemia.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Agaram, Narasimhan P; Chen, Chun-Liang; Zhang, Lei et al. (2014) Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes Cancer 53:779-87
Antonescu, Cristina R; Chen, Hsiao-Wei; Zhang, Lei et al. (2014) ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer 53:951-9
Kohsaka, Shinji; Shukla, Neerav; Ameur, Nabahet et al. (2014) A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46:595-600
Kim, Teresa S; Cavnar, Michael J; Cohen, Noah A et al. (2014) Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res 20:2350-62
Qin, Li-Xuan; Breeden, Linda; Self, Steven G (2014) Finding gene clusters for a replicated time course study. BMC Res Notes 7:60
Brennan, Murray F; Antonescu, Cristina R; Moraco, Nicole et al. (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260:416-21; discussion 421-2
Patwardhan, Parag P; Surriga, Oliver; Beckman, Michael J et al. (2014) Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res 20:3146-58
Weinreb, Ilan; Zhang, Lei; Tirunagari, Laxmi M S et al. (2014) Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer 53:845-56
Antonescu, Cristina R; Sung, Yun-Shao; Chen, Chun-Liang et al. (2014) Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. Genes Chromosomes Cancer 53:183-93
Lee, William; Teckie, Sewit; Wiesner, Thomas et al. (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227-32

Showing the most recent 10 out of 37 publications